Taysha Gene Therapies
(NASDAQ) TSHA
Taysha Gene Therapies Financials at a Glance
Market Cap
$1.17B
Revenue (TTM)
$9.77M
Net Income (TTM)
$108.99M
EPS (TTM)
$-0.36
P/E Ratio
-11.29
Dividend
$0.00
Beta (Volatility)
1.73 (High)
Dividend
$0.00
Beta (Volatility)
1.73 (High)
Price
$4.08
Volume
82,609
Open
$4.25
Price
$4.08
Volume
82,609
Open
$4.25
Previous Close
$4.08
Daily Range
$4.04 - $4.29
52-Week Range
$1.05 - $6.02
Dividend
$0.00
Beta (Volatility)
1.73 (High)
Price
$4.08
Volume
82,609
Open
$4.25
Previous Close
$4.08
Daily Range
$4.04 - $4.29
52-Week Range
$1.05 - $6.02
TSHA News
TSHA: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Taysha Gene Therapies
Industry
Biotechnology
Sector
Health CareEmployees
99
CEO
Sean P. Nolan
Website
www.tayshagtx.comHeadquarters
Dallas, TX 75247, US
TSHA Financials
Key Financial Metrics (TTM)
Gross Margin
94%
Operating Margin
-11%
Net Income Margin
-11%
Return on Equity
-68%
Return on Capital
-35%
Return on Assets
-32%
Earnings Yield
-8.86%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$1.17B
Shares Outstanding
287.27M
Volume
82.61K
Short Interest
0.00%
Avg. Volume
2.71M
Financials (TTM)
Gross Profit
$8.63M
Operating Income
$110.50M
EBITDA
$109.35M
Operating Cash Flow
$93.09M
Capital Expenditure
$738.00K
Free Cash Flow
$93.83M
Cash & ST Invst.
$319.77M
Total Debt
$18.17M
Taysha Gene Therapies Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$5.49M
+171.3%
Gross Profit
$5.19M
+156.5%
Gross Margin
94.55%
N/A
Market Cap
$1.17B
N/A
Market Cap/Employee
$16.02M
N/A
Employees
73
N/A
Net Income
$27.85M
-48.3%
EBITDA
$28.00M
-51.7%
Quarterly Fundamentals
Net Cash
$301.60M
+297.6%
Accounts Receivable
$0.00
N/A
Inventory
$0.00
N/A
Long Term Debt
$18.17M
-70.4%
Short Term Debt
$0.00
-100.0%
Return on Assets
-31.75%
N/A
Return on Invested Capital
-34.88%
N/A
Free Cash Flow
$26.97M
-47.3%
Operating Cash Flow
$26.72M
-46.0%